Q1 Earnings Forecast for FibroGen Issued By HC Wainwright

FibroGen, Inc. (NASDAQ:FGEN) – Analysts at HC Wainwright issued their Q1 2025 earnings estimates for shares of FibroGen in a research note issued on Tuesday, March 18th. HC Wainwright analyst M. Keller forecasts that the biopharmaceutical company will post earnings per share of $0.04 for the quarter. HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for FibroGen’s current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for FibroGen’s Q2 2025 earnings at $0.05 EPS, Q3 2025 earnings at ($0.15) EPS, Q4 2025 earnings at ($0.17) EPS, FY2025 earnings at ($0.31) EPS and FY2026 earnings at ($0.69) EPS.

Separately, StockNews.com began coverage on shares of FibroGen in a research note on Friday, March 14th. They set a “hold” rating for the company.

FibroGen Stock Performance

FGEN opened at $0.34 on Thursday. The business’s fifty day moving average is $0.49 and its two-hundred day moving average is $0.43. FibroGen has a one year low of $0.18 and a one year high of $2.80. The company has a market cap of $33.91 million, a price-to-earnings ratio of -0.27 and a beta of 0.82.

FibroGen (NASDAQ:FGEN) last issued its earnings results on Monday, March 17th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.08). The company had revenue of $3.14 million during the quarter, compared to analysts’ expectations of $24.91 million.

Institutional Trading of FibroGen

A number of large investors have recently made changes to their positions in FGEN. JPMorgan Chase & Co. lifted its holdings in FibroGen by 430.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,673,555 shares of the biopharmaceutical company’s stock valued at $668,000 after purchasing an additional 1,358,194 shares in the last quarter. Renaissance Technologies LLC lifted its stake in shares of FibroGen by 80.4% during the fourth quarter. Renaissance Technologies LLC now owns 1,358,712 shares of the biopharmaceutical company’s stock valued at $719,000 after buying an additional 605,572 shares during the period. Geode Capital Management LLC lifted its stake in shares of FibroGen by 3.1% during the third quarter. Geode Capital Management LLC now owns 1,083,521 shares of the biopharmaceutical company’s stock valued at $433,000 after buying an additional 32,884 shares during the period. Two Sigma Advisers LP boosted its position in FibroGen by 18.3% during the fourth quarter. Two Sigma Advisers LP now owns 878,400 shares of the biopharmaceutical company’s stock worth $465,000 after acquiring an additional 135,600 shares during the last quarter. Finally, Two Sigma Investments LP grew its stake in FibroGen by 19.6% in the 4th quarter. Two Sigma Investments LP now owns 604,421 shares of the biopharmaceutical company’s stock worth $320,000 after acquiring an additional 98,888 shares during the period. Institutional investors and hedge funds own 72.71% of the company’s stock.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.